Day One Biopharmaceuticals Inc (DAWN NASDAQ) stock market data APIs
$6.7355
-0.45(-6.7%)
as of May 8, 2025
Day One Biopharmaceuticals Inc Financial Data Overview
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Prev. Close
6.7355
Open
6.2837
High
6.9811
Low
6.2837
52 wk Range
6.26-17.14
Market Cap
804 M
Shares Outstanding
101 M
Revenue
131 M
EPS
-0.63
Beta
-1.247
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Day One Biopharmaceuticals Inc data using free add-ons & libraries
Get Day One Biopharmaceuticals Inc Fundamental Data
Day One Biopharmaceuticals Inc Fundamental data includes:
- Net Revenue: 131 M
- EBITDA: -210 708 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Day One Biopharmaceuticals Inc News
New
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 millio...
Q1 2025 American International Group Inc Earnings Call
Participants Quentin McMillan; Vice President, Managing Director and Head of Investor Relations; American International Group Inc Peter Zaffino; Chairman of the Board, Chief Executive Officer; Ameri...
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercia...
Exploring US High Growth Tech Stocks This April 2025
Amidst a backdrop of heightened market volatility driven by recent tariff implementations and retaliatory measures, the U.S. stock market has experienced significant fluctuations, with key indices lik...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
